mRNA 백신 및 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global mRNA vaccine and therapeutics market size is expected to reach USD 114.50 Billion in 2034 from USD 31.74 Billion in 2025, growing at a CAGR of 15.32% during 2026-2034.The Global mRNA Vaccine and Therapeutics Market witnessed exponential growth following the successful deployment of mRNA-based COVID-19 vaccines. The technology demonstrated rapid development capabilities, high efficacy, and scalability, transforming vaccine research and production. Beyond infectious diseases, mRNA platforms are being explored for cancer immunotherapy, rare genetic disorders, and personalized medicine applications.

Key growth drivers include substantial government funding, ongoing R&D investments, and expanding biotech partnerships. Advances in lipid nanoparticle delivery systems and improved mRNA stability have strengthened clinical outcomes. The platform's adaptability allows quick modification to target emerging pathogens, making it highly valuable in global public health preparedness strategies.

Future prospects are exceptionally strong as pharmaceutical companies expand pipelines for oncology, autoimmune, and metabolic diseases. Continuous improvements in storage, distribution, and manufacturing processes will enhance commercial viability. As research broadens therapeutic indications, mRNA technology is expected to revolutionize modern medicine, ensuring sustained long-term market growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By mRNA Type

Nucleoside-modified mRNA

Unmodified mRNA

Self-amplifying mRNA

By Type

• Prophylactic
• Therapeutic

By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Others (Respiratory Diseases, etc)

By End-user

• Hospitals & Clinics
• Biopharmaceutical Companies
• Others

COMPANIES PROFILED

• Moderna, BioNTech, Pfizer, Sanofi, CureVac, Arcturus Therapeutics, GSK, CSL/Seqirus, Ethris, eTheRNA, Capstan Therapeutics, ReNAgade Therapeutics, Tiba Biotech, Acuitas Therapeutics, Strand Therapeutics, Replicate Bioscience, Omega Therapeutics, Cartesian Therapeutics, Sana Biotechnology, Abogen

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY MRNA TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Mrna Type
• 4.2. Nucleoside-modified mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Unmodified mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Self-amplifying mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Prophylactic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Rare Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Others (Respiratory Diseases, etc) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY END-USER 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.2.1 By Mrna Type
  • 8.2.2 By Type
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.3.1 By Mrna Type
  • 8.3.2 By Type
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.4.1 By Mrna Type
  • 8.4.2 By Type
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.5.1 By Mrna Type
  • 8.5.2 By Type
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.6.1 By Mrna Type
  • 8.6.2 By Type
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MRNA VACCINE AND THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Moderna
  • 10.2.2 BioNTech
  • 10.2.3 Pfizer
  • 10.2.4 Sanofi
  • 10.2.5 CureVac
  • 10.2.6 Arcturus Therapeutics
  • 10.2.7 GSK
  • 10.2.8 CSL/Seqirus
  • 10.2.9 Ethris
  • 10.2.10 ETheRNA
  • 10.2.11 Capstan Therapeutics
  • 10.2.12 ReNAgade Therapeutics
  • 10.2.13 Tiba Biotech
  • 10.2.14 Acuitas Therapeutics
  • 10.2.15 Strand Therapeutics
  • 10.2.16 Replicate Bioscience
  • 10.2.17 Omega Therapeutics
  • 10.2.18 Cartesian Therapeutics
  • 10.2.19 Sana Biotechnology
  • 10.2.20 Abogen